Bioanalysis Zone

Business of bioanalysis: Investing in emerging bioanalytical technologies

This entry is part 2 of 4 in the series Business of Bioanalysis

In part 1 of this 3-part video filmed in Los Angeles (CA, USA) our panel of experts discuss investing in emerging bioanalytical technologies – when is too soon and when is too late? Acquisition of new tools to address unmet analytical needs requires practical considerations, such as platform reliability, scalability from discovery to the regulated environment and total cost of ownership. This includes hiring and training appropriate subject matter experts, managing software validation and accurately reading the bioanalytical marketplace.

Panelists:

Scott Fountain (Charles River Laboratories), Zamas Lam (QPS), Roger Hayes (MPI Research), Yan Zhang (Bristol-Myers Squibb), Ola Saad (Genentech), and Afshin Safavi (BioAgilytix)

To view restricted content, please:

Discussions include:

  • When is the right time to invest in new technology?
  • Who should be driving the science forward, CRO, Pharma, vendor?
  • Perspectives on the benefits of introducing new technologies
  • The considerations CROs and Pharmas have to make before investing in and implementing new technologies
  • What new talent brings to the table when considering new technology
  • Balancing investment in instruments with investment in talent
  • How CROs and Pharmas identify, recruit and retain talented individuals

Back to: Business of bioanalysis – Home page

Click here to view the next video: Managing the pipeline of bioanalytical talent and staff

Series Navigation<< Business of bioanalysis: Bioanalysis Zone panel discussionBusiness of bioanalysis: Managing the pipeline of bioanalytical talent and staff >>
Share: